Navigation Links
Myeloma in Medical Technology

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... breast and prostate cancer) or multiple myeloma and bone metastases. Secondary endpoints were to ... to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential ... with incidence rates of nearly 100 percent in myeloma patients and as high as 75 percent in solid tumor ...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

... Phase 2 Trial of Relapsed and Refractory Multiple myeloma Patients - Proteolix Expands Trial ORLANDO, ... trial of relapsed and refractory multiple myeloma patients were presented today in an oral session by Sundar Jagannath, M.D., Chief of the Multiple myeloma Program, Bone Marrow and Blood Stem Cell ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... a Phase 3 clinical trial in relapsed multiple myeloma patients." About Carfilzomib Carfilzomib ... by Proteolix in collaboration with the Multiple myeloma Research Consortium (MMRC). A Phase Ib clinical ... dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is ...

New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers

... reduce the number of cancerous cells in multiple myeloma patients and improve patient health and ... a Phase 1 trial in patients with multiple myeloma and to date six patients have been treated at The ... is seeking to enroll another nine multiple myeloma patients with the kappa form of the disease to be ...

XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma

... ("rHuEPO") for the prolongation of multiple myeloma ("MM") patients' survival and improvement of ... and cancer-related anemia. ABOUT MULTIPLE myeloma Currently incurable, MM is a severe plasma ... of therapeutics for the treatment of multiple myeloma and hepatitis C. XTL will be developing rHuEPO ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

... featured at the 12th International Multiple myeloma Workshop in Washington, DC, highlights a subset ... with Relapsed or Relapsed / Refractory Multiple myeloma Who Were Previously Treated with Bortezomib." ... multiple myeloma." One additional multiple myeloma clinical poster was presented as follows: ...

Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results

... is approved for the treatment of multiple myeloma alone and in addition to chemotherapy. ... this US-based Phase 1 study included 39 multiple myeloma patients at three clinical oncology sites. Noted oncologist and myeloma specialist, Dr. James R. Berenson was Principal ...

EntreMed Presents Initial Clinical Results for ENMD-2076

... from the FDA for the treatment of multiple myeloma using ENMD-2076. To further enhance its clinical ... A Phase 1 study with ENMD-2076 in multiple myeloma is currently underway. Orphan drug is a ... initiation of the previously announced multiple myeloma study and the expected commencement of the ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to ... Clinical Director of the Jerome Lipper Multiple myeloma Center at the Dana-Farber Cancer Institute ... with Relapsed or Relapsed / Refractory Multiple myeloma Who Were Previously Treated with Bortezomib," has ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... for patients with previously untreated multiple myeloma given VELCADE, melphalan and prednisone (VcMP). ... "The ultimate goal in treating multiple myeloma is to prolong the patient's life," said Professor ... 682 patients with previously untreated multiple myeloma ineligible for stem cell transplantation. The ...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

... of Bortezomib in patients with multiple myeloma who have undergone high-dose melphalan therapy ... Lysis Syndrome Multiple myeloma Jeffrey Matous, M.D., Rocky ... adult patients with advanced refractory multiple myeloma Waldenstrom ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... patients with previously untreated multiple myeloma (MM). Prolonged progression-free survival (PFS) ... In a Phase III study conducted by the Italian myeloma Network GIMEMA, researchers compared VcTD with TD ... for three 21-day cycles. About Multiple myeloma ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... "We are committed to advancing multiple myeloma treatment that delivers the best patient ... regimens for previously untreated multiple myeloma patients." During Phase I, patients ... safety and tolerability. About Multiple myeloma ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... leukemia, cutaneous t-cell lymphoma, multiple myeloma and mantle cell lymphoma ... Adult Patients with Advanced Refractory Multiple myeloma (ASH Abstract #2774 : Sunday, December 7, ... acid) is indicated for patients with multiple myeloma and documented bone metastases from solid tumors ...

Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

... 2 clinical trials of carfilzomib in multiple myeloma will be presented at the upcoming 50th Annual ... Sundar Jagannath, M.D., Chief of the Multiple myeloma Program, Bone Marrow and Blood Stem Cell ... of patients with relapsed and refractory multiple myeloma during the Novel Therapies ...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

... Key Findings The trial in advanced multiple myeloma is a randomized, multi-center, open-label Phase 2 ... across all treatment groups. The multiple myeloma study is ongoing, and 58 patients in this ... specific cancers: -- Patients in the multiple myeloma trial will continue on treatment until the ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... (MP) alone in previously untreated multiple myeloma patients. Multiple myeloma is the second most common blood cancer. (Logo: ... for patients with previously untreated multiple myeloma on June 20, 2008. The Phase III VISTA trial was ...

Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma

... is indicated for use in patients with multiple myeloma who have had at least one prior therapy. Patients ... in the treatment of patients with multiple myeloma for whom treatment options may be limited." ... as a single agent for the treatment of multiple myeloma in two Phase 2 clinical trials. A Phase 2 ...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

... presented by Antonio Palumbo, M.D., Chief of the myeloma Unit; Department of Hematology, University of ... by modified EBMT criteria and International myeloma Working Group criteria. Results were presented by ... was observed. About Multiple Myeloma Multiple myeloma is the second most common hematologic malignancy ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... with VcD. About Multiple Myeloma Multiple myeloma is the second most common hematologic malignancy ... for the treatment of patients with multiple myeloma who have received at least one prior therapy. ... rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were ...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... Doxorubicin Plus Bortezomib in Multiple myeloma Patients with Renal Insufficiency (Abstract ... for the treatment of patients with multiple myeloma who have not previously received VELCADE and have ... injury -- In the randomized multiple myeloma study, 25 patients (8%) in the VELCADE ...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

... of VELCADE Combinations in Front-line Multiple myeloma - CAMBRIDGE, Mass., May 16 /PRNewswire/ -- ... the market leader in relapsed multiple myeloma and the only drug approved for the treatment of ... Bart Barlogie, M.D., Ph.D., Director, myeloma Institute for Research and Therapy, ...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

... SNS-032 Demonstrates Activity in Multiple myeloma and Mantle Cell Lymphoma SOUTH SAN FRANCISCO, ... from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple myeloma Research Consortium (MMRC) and with the ...

Anti-Cancer Drug CYT997 Update

... clinical programs 1. Phase II trial in multiple myeloma Cytopia commenced dosing in its first Phase II ... in patients with relapsed or refractory multiple myeloma in January 2008, some four months after ... potential activity of this compound in multiple myeloma extends the utility of the drug beyond the core ...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

... for the treatment of patients with multiple myeloma who have received at least one prior therapy. ... day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were ... of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated ...

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

... treatment for patients with untreated multiple myeloma (MM), aged 65 years or older or ineligible for ... Thalidomide Pharmion for first line multiple myeloma in the 27 member states of the European Union ... people in the EU are diagnosed with multiple myeloma each year. Thalidomide Pharmion has been ...

Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology

... with advanced, relapsed/refractory multiple myeloma (MM) were presented on Saturday, December 8, 2007 ... Clinical Director of the Jerome Lipper Multiple myeloma Center at the Dana-Farber Cancer Institute ... IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE myeloma PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB: ...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

... and tolerability in patients with multiple myeloma who had previously progressed following treatment ... "Tanespimycin (T) + Bortezomib (BZ) in Multiple myeloma (MM): Confirmation of the Recommended Dose Using ... a potential treatment for patients with multiple myeloma who have failed prior regimens due to ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... in Newly Diagnosed Patients with Multiple myeloma - Malathi Hari, University of Michigan, Ann ... Therapeutic Advantage for High-Risk Multiple myeloma Patients Relapsing within 12 Months of Stem ... Alone in Relapsed or Refractory Multiple myeloma - Heather J. Sutherland, University of ...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

... III trials of VELCADE in front-line multiple myeloma to be featured as oral presentations at the ... the significant efficacy of VELCADE in multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). (Logo: ... therapy into the front-line multiple myeloma setting." Front-Line Multiple Myeloma Data to ...

Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies

... Nov. 1 /PRNewswire-USNewswire/ -- Multiple myeloma is one of the most common and devastating bone ... of the American Society of Hematology. Multiple myeloma (MM) is a neoplasm of plasma cells, a type of ... history and treatment options for multiple myeloma in this population." Improved Survival in ...

Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease

... of calcium levels, Velcura has chosen myeloma as its lead indication, as the bone fragility, ... life issues to affected patients. About Multiple myeloma Multiple myeloma is a blood malignancy characterized by ...

Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints

... trial in patients with newly diagnosed multiple myeloma showed that the therapy of VELCADE, melphalan and ... new standard of care for newly diagnosed multiple myeloma patients," said Paul Richardson, M.D., Associate ... School; Clinical Director, Jerome Lipper Multiple myeloma Center Dana-Farber Cancer Institute Boston; and a ...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

... we have received from the US and international myeloma clinician and patient communities." About TIME ... enroll over 450 patients with relapse of multiple myeloma following a single prior course of treatment ... of drug-sensitive and drug-resistant multiple myeloma cell lines. Tanespimycin also inhibits expression ...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... survival. Objective response rate in multiple myeloma is measured primarily by the patient's level ... of drug-sensitive and drug-resistant multiple myeloma cell lines. Tanespimycin also inhibits expression ... drug designation for tanespimycin in multiple myeloma in both the US and European Union. About Kosan ...

Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint

... positive results in multiple myeloma (MM) similar to those reported two weeks ago in ... stem cell transplant (HSCT) for multiple myeloma at medical centers in the United States, Canada, ... and European regulatory approval in both multiple myeloma and lymphoma in the first half of 2008. The ...

Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor

... Chief Executive Officer of the MMRC, as well as a myeloma patient. "This trial and the others the MMRC is ... in helping to slow or stop the growth of multiple myeloma cells. Preclinical laboratory data suggests that LBH589 has significant activity against multiple myeloma cells, including those that are resistant to ...

Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

... highly active and novel multiple myeloma agents -- CAMBRIDGE, Mass., Aug. 15 ... and cyclophosphamide in the front-line multiple myeloma (MM) setting. The trial, named EVOLUTION(1), will ... at http://www.velcade.com . About Multiple myeloma ...

The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma

... Conn., Aug. 15 /PRNewswire/ -- The Multiple myeloma Research Consortium (MMRC) and Proteolix, Inc. ... class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix ... to bring better, more effective treatments to myeloma patients as quickly as possible." The trial will ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases ... types of advanced cancer, with incidence rates of nearly 100 percent in myeloma patients and as high as 75 percent in breast and prostate cancer patients. ...
Other Contents
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s ... new study providing evidence on the impact of 100% ... , Sufficient enough evidence already exists showing a negative ... drinks, with the onset of tooth decay. One question ... as 100% fruit juice, meaning it is completely natural ...
(Date:12/15/2014)... 2014 SIMpalm, a leading mobile ... for iPhone for its client, which allows users to ... company, specialized in finding the right wine. At ... uses combined sensory, chemistry and wine information. All this ... “wine fingerprint.” Those wines that are close counterparts to ...
(Date:12/15/2014)... 2014 Health Dialog, a leading ... that it has received Patient Oriented Accreditation from ... its Disease Management (DM) Programs for asthma, congestive ... heart disease and diabetes. This marks the 12th ... Dialog’s Disease Management (DM) Programs, reaffirming Health Dialog’s ...
(Date:12/15/2014)... Expert pilots process visual information more efficiently than less ... during landings, a new study shows. Landing is ... master, and 36 percent of all airplane crashes and ... and landing. Researchers monitored the brain activity of ... they were at the controls of a flight simulator. ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was announced ... the category of Best Blog 2014. McAfee received the ... career blog Networking Ahead which combines many ... their talent and influence through better networking, leadership and ... Networking Ahead for Business, has been motivating readers for ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
Other TagsOther Tags